Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: A population-based UK cohort study using electronic health records

World Psychiatry

Volumn 15, Issue 1, 2016, Pages 53-58

  Hayes, Joseph F ^a   Marston, Louise ^a   Walters, Kate ^a   Geddes, John R ^b   King, Michael ^a   Osborn, David P J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bipolar disorder; Cohort study; Electronic health records; Lithium; Maintenance treatment; Olanzapine; Quetiapine; Valproate

Indexed keywords

LITHIUM SALT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; COHORT ANALYSIS; DRUG TREATMENT FAILURE; ELECTRONIC HEALTH RECORD; ENGLAND; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84964969763     PISSN: 17238617     EISSN: 20515545     Source Type: Journal    
DOI: 10.1002/wps.20298     Document Type: Article

References (44)

1. Saunders KE, Goodwin GM. The course of bipolar disorder. Adv Psychiatr Treat 2010;16:318-28.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
3. Perlis RH, Ostacher MJ, Patel JK et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163: 217-24.
4. Hayes J, Prah P, Nazareth I et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS One 2011;6:e28725.
5. National Institute for Health and Care Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. GC38. London: National Institute for Health and Care Excellence, 2006.
6. American Psychiatric Association. American Psychiatric Association practice guideline for the treatment of patients with bipolar disorder. Washington: American Psychiatric Association, 2002.
7. Mok YM, Chan HN, Chee KS et al. Ministry of Health clinical practice guidelines: bipolar disorder. Singapore Med J 2011;52:914-8.
8. Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013; 15:1-44.
9. Miura T, Noma H, Furukawa TA et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1:351-9.
10. Severus E, Taylor MJ, Sauer C et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014;2:15.
11. National Institute for Health and Care Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. GC185. London: National Institute for Health and Care Excellence, 2014.
12. Reed C, Novick D, Gonzalez-Pinto A et al. Observational study designs for bipolar disorder - What can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry 2009;33:715-21.
13. Baldessarini RJ Treatment research in bipolar disorder. CNS Drugs 2002; 16:721-9.
14. Lancet Editors. Cross design synthesis: a new strategy for studying medical outcomes? Lancet 1992;340:944-6.
15. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996;312:1215-8.
16. Baldessarini RJ, Tohen M, Tondo L. Maintenance treatment in bipolar disorder. Arch Gen Psychiatry 2000;57:490-2.
17. IMS Health. Our data. www.epic-uk.org.
18. Chisholm J. The Read clinical classification. BMJ 1990;300:1092.
19. Dave S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 2009;18:704-7.
20. Health and Social Care Information Centre. Prescriptions dispensed in the community, Statistics for England - 2001-2011. Leeds: Health and Social Care Information Centre, 2012.
21. Blak B, Thompson M, Bourke A. National representativeness and data quality of The Health Improvement Network (THIN) database of primary care information for epidemiological research. Presented at the 9th Annual Conference of the UK Federation of Primary Care Research, Liverpool, November 2006.
22. Blak BT, Thompson M, Dattani H et al. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251-5.
23. Lis Y, Mann RD. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol 1995;48:431-43.
24. Hardoon S, Hayes JF, Blackburn R et al. Recording of severe mental illness in United Kingdom primary care, 2000-2010. PLoS One 2013;8:e82365.
25. Nazareth I, King M, Haines A et al. Accuracy of diagnosis of psychosis on general practice computer system. BMJ 1993;307:32-4.
26. Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases. Pharmacoepidemiol Drug Saf 2013;22:64-9.
27. Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18:76-83.
28. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24.
29. Holmes WM Using propensity scores in quasi-experimental designs. Thousand Oaks: Sage Publications, 2013.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
31. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol 1999;150:327-33.
32. Austin PC, Mamdani MM, Stukel TA et al. The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med 2005;24:1563-78.
33. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002;2:358-77.
34. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
35. d'Agostino RB. Tutorial in biostatistics: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
36. Lin TH, Dayton CM. Model selection information criteria for non-nested latent class models. J Educ Behav Stat 1997;22:249-64.
37. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985;39:33-8.
38. Stata. Release 13. Statistical Software, 2013.
39. Sajatovic M, Valenstein M, Blow FC et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8:232-41.
40. Sajatovic M, Valenstein M, Blow F et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007;58:855-63.
41. Geddes J, Goodwin G, Rendell J et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385-95.
42. Eder U, Mangweth B, Ebenbichler C et al. Association of olanzapineinduced weight gain with an increase in body fat. Am J Psychiatry 2001; 158:1719-22.
43. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004;161:3-18.
44. Shine B, McKnight RF, Leaver L et al. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015;386:461-8.